Health Care

A single dose of an experimental gene therapy boosted production of a missing blood-clotting factor in people with hemophilia, a new study shows.

Results from studies presented March 6 at the Conference on Retroviruses & Opportunistic Infections in Seattle demonstrated the importance of identifying & treating HIV-infected infants within the first year of life to prevent harm to the immune system & to enable normal neurological development.

Tracey Mumford from The Michael J. Fox Foundation discusses Parkinson's disease, the Foundation’s work toward a cure, and partnerships they're currently seeking. The Foundation will be one of the patient advocacy groups attending the 2012 BIO International Convention on June 18-21 in Boston, Mass.  

Gary Godsey, President and CEO of the PKD Foundation, explains what resources the Foundation provides for patients and how they're working with researchers to repurpose compounds through the "Accelerating Treatment to Patients” initiative. He encourages listeners to take the 31 Day PKD Challenge as part of National Kidney Month and to join him on Facebook.

Lisa Tate, CEO of WomenHeart, the National Coalition for Women with Heart Disease, discusses what we can each do to prevent heart disease.

Drugs approved with companion diagnostic tests represent the next wave of personalized medicine and have the potential to significantly improve patient outcomes.

BIO Asia will be held January 31 – February 1, 2012 in Osaka, Japan.

Learn about the role biotechnology plays in the on-going fight against HIV/AIDS.

Diseases of the eye affect more than 10 million Americans, and biotechnology holds great promise for treatments and cures

In three minutes, this video tells the pertinent story of how recombinant DNA technology was used to produce human — or synthetic — insulin in large amounts and how it became the first biotechnology treatment approved by the FDA.

BIOtech-NOW talks to Laurence Marton, Co-Chair of the Personalized Medicine World Conference 2012, about the outlook for personalized medicine.

The world's best hope for turning breast cancer — and other forms of cancer — into a chronic manageable disease lies within biotechnology.

BIO President and CEO Jim Greenwood congratulated the FDA and biopharmaceutical sponsors for making 35 novel new treatments available to patients in FY11.

Underlying the PDUFA V recommendations are the principles that a science-based, transparent, and well-managed review process that appropriately balances benefits and risks can enhance public trust and increase patient access to new medicines.

July 31 2014
The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments on the “The Food and Drug Administration Fiscal Year 2014-2018 Strategic Priorities.”
July 22 2014
The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments on the “Expedited Access for Premarket Approval Medical Devices Intended for Unmet Medical Need for Life Threatening or Irreversibly Debilitating Diseases or Conditions; Draft Guidance for Industry and Food and Drug Administration Staff.”
June 9 2014
The Biotechnology Industry Organization (BIO) is pleased to submit the following comments on the draft guidance issued by the Food and Drug Administration (FDA) on April 9, 2014, entitled “Draft Guidance for Industry, Researchers, Patient Groups, and Food and Drug Administration Staff: Meetings with the Office of Orphan Products Development.”
May 27 2014
 The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments on the Draft Guidance for Industry on Labeling for Human Prescription Drug and Biological Products Approved Under the Accelerated Approval Regulatory Pathway.
May 20 2014
The importance of supporting biomedical research and innovation and the development of new therapies cannot be overstated. Today, we face increasing competition around the globe to overtake U.S. world leadership in biomedical innovation. Even in this time of budgetary constraint, it is crucial that we not allow this to happen. We cannot afford to lose the next generation of discoveries that address one of the nation’s leading cost drivers – chronic and debilitating disease.
April 7 2014
The EXPIRE Act would extend tax credits that expired at the end of 2013, including several of importance to the biotechnology industry.
March 25 2014
The Biotechnology Industry Organization (BIO) and the Indiana Health Industry Forum (IHIF) commend Indiana Governor Mike Pence for signing legislation today designed to create a pathway for the substitution of interchangeable biologic medicines.
March 5 2014
Many of the provisions included in this budget proposal would jeopardize the continued biotech research and development that is necessary to find cures and breakthrough medicines for patients living with debilitating and life-threatening diseases. 
January 30 2014
Patients Should Be Informed if Doctor's Prescription Changed